The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | How can MM patients become involved in the clinical trial networks?
Rakesh Popat, MD, PhD, from University College London, London, UK talks to us about the major advancements in multiple myeloma (MM), namely the new cutting-edge technologies and multiple Clinical Trial Networks run by Myeloma UK across the UK. He encourages MM patients to become involved with the trial network and advises them to consult their physician for further information and hopes that this establishment will benefit patients and the research community. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
